Agency for Medicinal Products and Medical Devices of the Republic of Slovenia (JAZMP) hosted members of the European Integrated Price Information Database (EURIPID) on May 13 and 14, 2025. The meeting was attended by 30 representatives from 19 European countries. Held at the Union Hotel, the event brought together key stakeholders to collaborate on improving the EURIPID database and advancing public health initiatives.
What is EURIPID?
EURIPID (European Integrated Price Information Database) is a voluntary network of European countries dedicated to the confidential exchange of official medicine prices. It serves as an important tool to support medicine pricing and reimbursement policies and plays an increasingly vital role in ensuring transparency, fairness, and sustainability amid growing pressures on healthcare budgets.
Why is EURIPID important?
- It strengthens solidarity and trust among countries by enabling price comparisons through a secure system, providing a more balanced negotiating position, especially for smaller and medium-sized countries.
- It supports fairer access to medicines by facilitating more effective use of external price referencing (EPR) models, leading to fairer and more affordable prices for patients.
- It enables better decision-making based on reliable and official data, which is crucial for developing comprehensive, evidence-based pharmaceutical policies.
- It contributes to the sustainability of healthcare systems by increasing transparency in the pharmaceutical market and promoting more efficient use of public funds.
Meeting Highlights
The first day focused on internal organizational matters. The Executive Board of the Board of Participants (BoP), led by JAZMP Director Momir Radulović, provided updates on database development and future activities. Discussions covered formal procedures, voting, and strategic challenges, with an emphasis on improving services and international cooperation. The day concluded with a productive dialogue on how to better support EURIPID members’ activities and streamline data provision for researchers.
The second day looked toward the future of the EURIPID database. Participants discussed possibilities for expanding the database’s scope, strengthening its capabilities, and reviewing technical guidelines. The discussions aimed to ensure the sustainability and growth of EURIPID as a robust tool for public health and medicine pricing.
The central theme of the meeting was the importance of collaboration and innovation in public health, highlighting the commitment to improving the EURIPID database and achieving shared goals for medicine price transparency across Europe, ultimately leading to better healthcare. Active participation from all attendees is essential for implementing initiatives and ensuring that EURIPID continues to be a valuable data source for public health professionals and policymakers.
Who is behind EURIPID?
The network consists of member states that participate voluntarily but share a unified vision – to create a stronger and more coordinated European space in the field of medicine pricing. It is operationally led by the Executive Board and strategically guided by the Board of Participants with country delegates.
The project is supported by the European Commission and is part of broader efforts to ensure accessible and affordable medicines for all.
Photo: Marijo Zupanov
